載入中
NASDAQHealthcareMedical - Devices
最新資料
US$4.14
+US$0.08 · +1.97%
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
最新資料
US$4.14
+US$0.08 · +1.97%
盤中時間採用ET。市場資料可能有所延遲。
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
盤中時間採用ET。市場資料可能有所延遲。
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 4515.1萬 USD | 2943.1萬 USD | 1851.1萬 USD | 1239.8萬 USD | 840.1萬 USD |
| 銷貨成本 | 696.5萬 USD | 410.3萬 USD | 260.5萬 USD | 225.8萬 USD | 119.3萬 USD |
| 毛利 | 3818.6萬 USD | 2532.8萬 USD | 1590.6萬 USD | 1014萬 USD | 720.8萬 USD |
| 研究與開發 | 1496.5萬 USD | 1768.8萬 USD | 2983.5萬 USD | 2135.8萬 USD | 1422.4萬 USD |
| 銷售、一般及管理費用 | 5016.7萬 USD | 4380.5萬 USD | 4054.6萬 USD | 2522.1萬 USD | 1701.6萬 USD |
| 營業費用 | 6513.2萬 USD | 6149.3萬 USD | 7038.1萬 USD | 4657.9萬 USD | 3124萬 USD |
| 利息收入 | 55.5萬 USD | 40.4萬 USD | 43.1萬 USD | 18萬 USD | — |
| 利息支出 | 554.4萬 USD | 309萬 USD | 1.6萬 USD | 1000 USD | 176.1萬 USD |
| 折舊和攤銷 | 62.6萬 USD | 74.4萬 USD | 68.4萬 USD | 39.8萬 USD | 46.4萬 USD |
| 營業利益 | −2694.6萬 USD | −3616.5萬 USD | −5447.5萬 USD | −3643.9萬 USD | −2403.2萬 USD |
| 淨利 | −3922.7萬 USD | −3323.3萬 USD | −5936.3萬 USD | −4718.7萬 USD | −2884.5萬 USD |
公司資料更新於 2026年10月13日。
第三方分析師預期可能變動，並非 GoAI 建議。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
